SC0062 low dose

Phase 3Small molecule

BBiocity Biopharmaceutics Co., Ltd.

SC0062 low dose is one of 68 small molecule programs targeting IgA Nephropathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Iga NephropathyActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

Iga NephropathyPhase 3

Active, not recruiting

Chronic Kidney DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

540 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Aranesp

Amgen

Preclinical

40 2

SC0062 low dose

BBiocity Biopharmaceutics Co., Ltd.

Phase 3

1 3

Uloric

Takeda

Preclinical

3 4

Sovaldi

Gilead

Preclinical

1 5

Glucotrol

Pfizer

Preclinical

1 6

Vemlidy

Gilead

Preclinical

1 7

Flomax

Sanofi

Preclinical

—8

Miochol

BBausch Health Americas, Inc.

Preclinical

2 9

Epoetin Beta

Roche

Preclinical

5 10

PROCRIT

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Not yet recruiting

Injury

NCT06072326

Phase 3Recruiting

Iga Nephropathy

NCT06819826

Clinical

Trials by Indication[1]

IgA Nephropathy1 trial

A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria

Recruiting·BBiocity Biopharmaceutics Co., Ltd.·Phase 3·NCT06819826·360 enrolled

Injury1 trial

dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation

Not yet recruiting·UUniversity Medical Center Groningen·Phase 2·NCT06072326·36 enrolled

Chronic Kidney Disease1 trial

A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease

Active, not recruiting·BBiocity Biopharmaceutics Co., Ltd.·Phase 2·NCT05687890·255 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for SC0062 low dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SC0062 low dose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SC0062 low dose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biocity Biopharmaceutics Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBiocity Biopharmaceutics Co., Ltd.

SC0062 low dose

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

IgA Nephropathy1 trial

Injury1 trial

Chronic Kidney Disease1 trial

References

Drug Info

Quick Facts

Related News